Mirvetuximab Soravtansine

1 Drug classified under this active ingredient

Monoclonal Antibody. Mirvetuximab Soravtansine 5 mg/ml.
VIAL. 1 X 100 mg. Conc. for sol. for inf.
Dose:  6 mg/kg adj. ideal body weight (AIBW) admin. once every 3 weeks (21-day cycle) as an IV inf. until dis. progress. or unacceptable tox.
For adlts with FRα-positive, platinum resist. epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received 1-3  prior syst. tmt. regimens.
C/I: Hypersens.